REFERENCES
- National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update. Kidney Dis. 2000; 37: S182–S238
- Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006; 1: S19–S23
- Agarwal R. Transferrin saturation with intravenous irons—an in vitro study. Kidney Int. 2004; 66: 1139–1144
- Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004; 84: 1381–1478
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Annal Biochem. 1979; 95(2)351–358
- http://www.usrds.org/2005/pdf/09_cadiovascular_05.pdf, United States Renal Data System. Annual data report: Atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
- Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62: 1524–1538
- Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations—a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40: 90–103
- Lim CS, Vaziri ND. The effects of iron dextran on oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004; 65: 1802–1809
- Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000; 11: 539–549
- Tovbin D, Mazor D, Vorobiov M, et al. Induction of protein oxidation by intravenous iron in hemodialysis patients—role of inflammation. Am J Kidney Dis. 2002; 40: 1005–1012
- Cavdar C, Temiz A, Yeniçerioğlu Y, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol. 2003; 37(1)77–82
- Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106: 2212–2217
- Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002; 32(1)9–16
- Lim PS, Wei YH, Yu YL, et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999; 14: 2680–2687
- Legssyer R, Geisser P, McArdle H, et al. Comparison of injectable iron complexes in their ability to ironload tissues and to induce oxidative stress. Biometals. 2003; 16: 425–433
- Pai AB, Boyd AV, Charles R, et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007; 27(3)343–350
- Wyck D. Labile iron: Manifestations and clinical implications. J Am Soc Nephrol. 2004; 15: S107–S111